The Kerala government has directed over 6,000 government schools to renew K-FON internet connections and pay the bills ...
Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.
Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst ...
Petitioners challenge allotment order on the ground that a large number of flats reserved for EWS/BPL category were allotted ...
After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum. The ...
Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion—of which Lilly will pay $2.8 billion upfront. The deal, set to ...
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of ...
Eli Lilly and Co. is expanding its mental health portfolio with the acquisition of AtaiBeckley, a psychedelic drug developer, ...
Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the ...
Under the terms of the deal, Lilly will purchase AtaiBeckley for $6.75 per share in cash. The healthcare leader will also pay ...
AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly ...
AtaiBeckley is being acquired by Eli Lilly at $6.75/share plus a $2.50 CVR—see the deal terms, milestone risks, and pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results